Understanding the Safety Concerns: How Many People Died in the Donanemab Trial?
•
3 min read
Three deaths were assessed as related to donanemab treatment due to amyloid-related imaging abnormalities (ARIA) during the TRAILBLAZER-ALZ 2 trial, prompting a closer examination of the drug's safety profile. The question of 'How many people died in the donanemab trial?' has become central to discussions surrounding this new Alzheimer's medication, balancing its efficacy with significant safety concerns.
